NXP800 for the Treatment of Patients With Advanced or Metastatic Cholangiocarcinoma

Advanced Cholangiocarcinoma Clinical Trial

Official title:

Phase 1b Study of the Novel GCN2 Kinase Activator NXP800 in Patients With Advanced Cholangiocarcionoma

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT06420349
• Other study ID #: MC230406
• Secondary ID: NCI-2024-03613MC
• Status: Recruiting
• Phase: Phase 1
• Start date: May 31, 2024
• Est. completion date: May 2026

Study information

• Verified date: June 2024
• Source: Mayo Clinic
• Contact: Clinical Trials Referral Office
• Phone: 855-776-0015
• Email: mayocliniccancerstudies[@]mayo.edu
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This phase I trial tests the safety, best dose, and effectiveness of NXP800 in treating patients with cholangiocarcinoma that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced) or that has spread from where it first started (primary site) to other places in the body (metastatic). NXP800 inhibits a pathway called the heat shock factor 1 (HSF1) pathway. The inhibition of this pathway inhibits proliferation, migration, survival, and metastasis in susceptible tumor cells. Overexpressed, amplified and/or overactivated in many cancer cells, HSF1 activates a set of genes that play a key role in tumor initiation, progression and metastasis. Inhibiting this pathway may in turn inhibit tumor initiation, progression, and/or metastasis. Giving NXP800 may be safe, tolerable and/or effective in treating patients with advanced or metastatic cholangiocarcinoma.

Description:

PRIMARY OBJECTIVE: I. To determine the maximum tolerated dose (MTD)/recommended phase 2 dose for heat shock factor 1 pathway inhibitor NXP800 (NXP800). SECONDARY OBJECTIVES: I. To determine the toxicity profile of NXP800. II. To determine the best response for NXP800 using Response Evaluation Criteria in Solid Tumors (RECIST) version (v)1.1. III. To estimate the overall survival (OS) for NXP800. IV. To estimate the progression-free survival (PFS) for NXP800. EXPLORATORY OBJECTIVES: I. To evaluate transcriptomic features associated with sensitivity, resistance and pharmacodynamic effect of NXP800 using serial ribonucleic acid-sequencing (RNA-Seq). II. To assess tumor evolution with NXP800 using serial whole genome-sequencing (Seq). III. To assess tumor evolution with NXP800 using serial circulating tumor deoxyribonucleic acid (DNA) (ct-DNA). IV. To estimate tumor marker response using serial CA19-9/carcinoembryonic antigen (CEA). OUTLINE: This is a dose de-escalation study of NXP800 followed by a dose-expansion study. Patients receive NXP800 orally (PO) once daily (QD) on days 1-28 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo computed tomography (CT), magnetic resonance imaging (MRI), and/or positron emission tomography (PET) at baseline and on study. Patients may optionally undergo ultrasound-guided liver biopsy and/or collection of blood samples on study and during follow up. After completion of study treatment, patients are followed up every 6 months until progressive disease or death for up to 3 years.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 30
• Est. completion date: May 2026
• Est. primary completion date: May 2026
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Age = 18 years
• Histologically/cytologically confirmed biliary tract cancer
• Advanced or metastatic disease that is refractory to gemcitabine or fluoropyrimidine based therapy, or if there is intolerance to these regimens
• Measurable disease by RECIST 1.1
• Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0 or 1
• Anticipated life expectancy of > 12 weeks
• Hemoglobin = 9.0 g/dL (obtained = 14 days prior to registration)
• Absolute neutrophil count (ANC) = 1500/mm^3 (obtained = 14 days prior to registration)
• Platelet count = 100,000/mm^3 (obtained = 14 days prior to registration)
• Aspartate aminotransferase (AST) = 2.5 x upper limit of normal (ULN) (obtained = 14 days prior to registration)
• Alanine aminotransferase (ALT) = 2.5 x ULN (obtained = 14 days prior to registration)
• Total bilirubin = 1.5 x ULN (obtained = 14 days prior to registration)
• Serum creatinine = 1.5 x ULN (obtained = 14 days prior to registration)
• Provide written informed consent
• Negative pregnancy test done = 7 days prior to registration, for persons of childbearing potential only
• NOTE: If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required
• Willing to use a highly effective method of contraception from the first dose of study medication through 180 days after the last dose of study medication, for persons of childbearing potential or persons able to father a child only
• Willing to return to enrolling institution for follow-up (during the active monitoring phase of the study)

Exclusion Criteria:

• Any of the following because this study involves an investigational agent whose genotoxic, mutagenic, and teratogenic effects on the developing fetus and newborn are

unknown:

• Pregnant persons.
• Nursing persons.
• Persons of childbearing potential who are unwilling to employ adequate contraception
• Systemic anti-neoplastic therapy or radiation therapy = 14 days prior to registration
• Major surgical procedure = 28 days prior to registration
• Ongoing therapy related events > grade 2
• Presence of another primary malignancy not in remission
• New York Heart Classification 3 or greater heart failure
• QT/corrected QT (QTc) interval > 470 ms using Fredericia's QT correction formula
• Uncontrolled brain metastatic disease
• Uncontrolled infection
• Any other comorbidities within the opinion of the investigator interfere with the investigation of the protocol
• Usage of drugs that strongly inhibit or induce CYP3A4 = 7 days prior to registration and for the duration of NXP800 dosing. Drugs that are low, medium, or other inhibitors of CYP3A4 are not prohibited and should be used with caution. Drugs that inhibit BCRP are not prohibited but should be used with caution, since NXP800 was found to be a BCRP substrate
• Usage of seville oranges, grapefruit or grapefruit juice or products = 7 days prior to registration and for the duration of NXP800 dosing
• Unwillingness to follow study related procedures
• Inability to provide informed consent

Related Conditions & MeSH terms

• Advanced Cholangiocarcinoma
• Cholangiocarcinoma
• Klatskin Tumor
• Metastatic Cholangiocarcinoma
• Refractory Cholangiocarcinoma
• Stage III Hilar Cholangiocarcinoma AJCC v8
• Stage III Intrahepatic Cholangiocarcinoma AJCC v8
• Stage IV Hilar Cholangiocarcinoma AJCC v8
• Stage IV Intrahepatic Cholangiocarcinoma AJCC v8

Intervention

Procedure:
• Biospecimen Collection
Undergo collection of blood samples
• Computed Tomography
Undergo CT

Biological:
• Heat Shock Factor 1 Pathway Inhibitor NXP800
Given PO

Procedure:
• Magnetic Resonance Imaging
Undergo MRI
• Positron Emission Tomography
Undergo PET
• Ultrasound-Guided Biopsy
Undergo ultrasound-guided liver biopsy

Locations

Country	Name	City	State
United States	Mayo Clinic in Arizona	Scottsdale	Arizona

Sponsors (1)

Lead Sponsor	Collaborator
Mayo Clinic

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Maximum tolerated dose (MTD)	MTD is defined as the dose level below the lowest dose that induces dose-limiting toxicity in at least one-third of patients.	Up to 12 months
Primary	Recommended phase 2 dose	Recommended phase 2 dose is based on MTD (Outcome 1).	Up to 12 months
Secondary	Incidence of adverse events	Overall toxicity incidence as well as toxicity profiles by dose level, patient and tumor site will be explored and summarized. Frequency distributions, graphical techniques and other descriptive measures will form the basis of these analyses. The grade 3+ adverse events will also be described and summarized in a similar fashion.	Up to 30 days after the administration of the last dose of study drug
Secondary	Best response	Best response is defined to be the best objective status recorded. The patient's best response assignment will depend on the achievement of both measurement and confirmation criteria. The Response Evaluation Criteria in Solid Tumors 1.1 criteria will be used for tumor evaluation and patients will be re-evaluated every 8 weeks. Responses will be summarized by simple descriptive summary statistics delineating complete and partial responses as well as stable and progressive disease in this patient population (overall and by dose level). The number of responses may indicate further evaluation for specific tumor types in a phase II setting.	Up to 3 years
Secondary	Overall survival (OS)	OS will be estimated using the Kaplan-Meier method. The median OS and corresponding 95% confidence interval (by Brookmeyer and Crowley) will be reported.	Up to 3 years
Secondary	Progression-free survival (PFS)	PFS will be estimated using the Kaplan-Meier method. The median PFS and corresponding 95% confidence interval (by Brookmeyer and Crowley) will be reported.	Up to 3 years

External Links

•   Mayo Clinic Clinical Trials